Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JMA Proposes Step-wise Integration of Health Insurance Programs
December 2, 2002
- CMIC: Annual Sales, Profits Increase Sharply
December 2, 2002
- Korosho to Create Database to Identify Similar Drugs
December 2, 2002
- ARKRAY to Push Healthcare Products Business
December 2, 2002
- Major Wholesalers Report Large Increases in Profits
December 2, 2002
- REGULATORY NEWS IN BRIEF
December 2, 2002
- Meet the Leaders (12)
December 2, 2002
- Kuraya Sanseido: Sales Up 3.8%, Profits Up 254.6%
December 2, 2002
- Olympus: Medical Systems Group Sales Up 9.3% to \127 Bil.
December 2, 2002
- Santen: Sales Up 6.1%, but Profits Down 41.6%
December 2, 2002
- Suzuken: Expansion of Pharmacy Market Drives Sales, Profits
December 2, 2002
- MEDICAL DEVICE NEWS IN BRIEF
December 2, 2002
- Kyorin: New Products Drive Increases in 1st-half Sales, Profits
December 2, 2002
- Azwell: "Painful Reforms" Bring Return to Profitability
December 2, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 2, 2002
- Mochida: NHI Price Cuts Affect Semiannual Sales, Profits
December 2, 2002
- Toho: Cost-cutting, Higher Margins Boost Sales, Profits
December 2, 2002
- Meiji Seika Discovers Enzymes Inactivating Abnormal Prion Protein
December 2, 2002
- Rohto: Profits Jump Despite Modest Increase in Sales
December 2, 2002
- Tanabe Seiyaku to Co-develop Altana's Roflumilast
December 2, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…